|
Shantha Biotechnics is an Indian biotechnology company based in Hyderabad. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India. The company is a wholly owned subsidiary of Sanofi group. ==History== The genesis of Shantha Biotechnics, Ltd. can be traced back to the initiatives of Dr. K I Varaprasad Reddy and Khalil Ahmed. Varaprasad and Ahmed established the company in 1993 to produce cost-effective drugs to reach the common man at an affordable price, while maintaining International standards in quality.〔 The project originated as an R&D outfit at the Osmania University under the industry-university interactive programme in 1993, and later operated out of the Center for Cellular and Molecular Biology until an independent R&D facility was built. In 2006, the European biotech major Mérieux Alliance bought 60% stake in Shantha Biotechnics at a valuation of $175 million. In 2009, the vaccine division of French pharmacological company Sanofi Pasteur acquired the stake held by Mérieux Alliance, valuing Shantha Biotech at Euro 550 million (over Rs 3,770 crore). Over time, Sanofi acquired further stake in Shantha Biotechnics and in 2013, acquired 100% of the company. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Shantha Biotechnics」の詳細全文を読む スポンサード リンク
|